bioAffinity Technologies Reports Substantial Doubt About Going Concern and Significant Losses for 2025

summarizeSummary

bioAffinity Technologies' 2025 annual report discloses a going concern warning, reporting a net loss of $14.9 million and a short cash runway, despite growth in core product revenue and progress in clinical development.

check_boxKey Events

• Going Concern Warning Issued

  Management has concluded there is substantial doubt about the company's ability to continue as a going concern beyond June 2026 without securing additional capital.

• Significant Financial Losses in 2025

  The company reported a net loss of $14.9 million for the year ended December 31, 2025, an increase from $9.0 million in 2024, with cash used in operating activities rising to $9.3 million.

• Core Product Revenue Growth

  Revenue from the flagship CyPath® Lung diagnostic test increased by 87% to $963,000 in 2025, although consolidated revenue decreased by 34% to $6.2 million due to strategic discontinuation of unprofitable pathology services.

• Large-Scale Clinical Study Initiated

  In March 2026, the company enrolled its first patient in a large-scale, 2,000-patient longitudinal clinical study for CyPath® Lung, a significant step for product validation.

auto_awesomeAnalysis

bioAffinity Technologies' annual report reveals a critical financial situation, with management expressing substantial doubt about the company's ability to continue as a going concern beyond June 2026 without additional funding. The company reported a net loss of $14.9 million for 2025, a significant increase from $9.0 million in 2024, and cash used in operations rose to $9.3 million. While the company successfully raised $16.9 million in equity during 2025, this was accompanied by substantial dilution and highlights an ongoing need for capital. Despite these financial challenges, the company reported positive operational developments, including 87% growth in its core CyPath® Lung diagnostic revenue, the initiation of a large-scale clinical study for the product, and advancements in its pipeline for asthma and COPD companion diagnostics. The company also confirmed a 1-for-30 reverse stock split in September 2025, likely to maintain its Nasdaq listing. Investors should closely monitor the company's ability to secure additional financing to support its operations and ongoing clinical development.